@article{Voss_E-2023_131798,
title = {Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study},
author = {Voss, E. and Shoaibi, A. and Yin Hui Lai, L. and Blacketer, C. and Alshammari, T. and Makadia, R. and Haynes, K. and Sena, A. and Rao, G. and van Sandijk, S. and Fraboulet, C. and Boyer, L. and Le Carrour, T. and Horban, S. and Morales, D. and Martínez Roldán, J. and Ramírez-Anguita, J. and Mayer, M. and de Wilde, M. and John, L. and Duarte-Salles, T. and Roel, E. and Pistillo, A. and Kolde, R. and Maljković, F. and Denaxas, S. and Papez, V. and Kahn, M. and Natarajan, K. and Reich, C. and Secora, A. and Minty, E. and Shah, N. and Posada, J. and Garcia Morales, M. and Bosca, D. and Cadenas Juanino, H. and Diaz Holgado, A. and Pedrera Jiménez, M. and Serrano Balazote, P. and García Barrio, N. and Şen, S. and Üresin, A. and Erdogan, B. and Belmans, L. and Byttebier, G. and Malbrain, M. and Dedman, D. and Cuccu, Z. and Vashisht, R.},
month = {apr},
year = {2023},
abstract = {Background: Adverse events of special interest (AESIs) were pre-specified to be monitored for the COVID-19 vaccines. Some AESIs are not only associated with the vaccines, but with COVID-19. Our aim was to characterise the incidence rates of AESIs following SARS-CoV-2 infection in patients and compare these to historical rates in the general population.},
volume = {58},
journal = {EClinicalMedicine},
publisher = {Elsevier},
url = {https://doi.org/10.1016/j.eclinm.2023.101932},
}
